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2882Although we agree that sickle cell disease–PH is multifactorial, the
hemodynamics of pre-capillary PH in SCD need to be clariﬁed. We
have deﬁned pre-capillary SCD-PH similar to other PAH sub-
groups: mean pulmonary arterial pressure 25 mm Hg with mean
pulmonary capillary wedge pressure or left ventricular end-diastolic
pressure 15 mm Hg, plus increased PVR. However, what consti-
tutes increased PVR in SCD differs from other PAH subgroups.
Anemia-induced elevation of cardiac output and reduction in blood
viscosity results in a lower pre-morbid PVR (3). In idiopathic PAH,
increased PVR is deﬁned as 240 dynes$s$cm–5, 2 SDs above the
pre-morbid PVR of80 to 120 dynes$s$cm–5. Three hemodynamic
studies (4–6) have demonstrated that SCD adults without PH had a
mean cardiac output of 8 to 9 l/min with a PVR of 72 to 74  25
to 38 dynes$s$cm–5. In the absence of a consensus deﬁnition
of elevated PVR in SCD, experts consider values that are 2 to 3 SDs
above normal (i.e., 160 dynes$s$cm–5) to be signiﬁcant.
We agree that the literature evaluating PAH therapy in SCD-
PH is limited. However, we also believe that the 3 clinical trials
conducted in these patients are insufﬁcient to determine whether
SCD patients with pre-capillary PH should receive PAH therapy.
These trials collectively enrolled only 14 patients with pre-capillary
PH (fewer than one-half of whom received vasodilators), resulting
in imprecisely estimated effects (7,8). There are 4 case series in
which SCD patients with pre-capillary PH were treated with
bosentan, sildenaﬁl, and/or epoprostenol. Vasodilator therapy led
to an increase in 6-min walk distance 41 to 144 m above baseline
(9–11), with improvements in mean pulmonary arterial pressure,
PVR, and cardiac index (11). On the basis of these studies com-
bined with our clinical experience, we weakly recommended a trial
of either an endothelin receptor antagonist or a prostacyclin analog
for select SCD patients with symptomatic pre-capillary PH. We
are concerned that the 2013 classiﬁcation will limit access for these
patients to clinically beneﬁcial PAH-speciﬁc medications.
The reclassiﬁcation of SCD-PH as Group IV, Group I, and now
as Group V reﬂects the imprecise nature of the classiﬁcation. It
stresses the need to deﬁne PH subgroups so that all patients may
beneﬁt from the available treatment options.*Elizabeth S. Klings, MD
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Sickle Cell Disease Beyond
Classiﬁcation Constraints
The Second World Symposium on Pulmonary Hypertension, held
in Evian, France, in 1998, settled the basis of the current classiﬁ-
cation system, representing a signiﬁcant step forward as compared
to the previous approach that separated pulmonary hypertension
(PH) into primary or secondary forms (1).
Since then, PH has been classiﬁed into 5 different categories
trying to group together patients sharing similar hemodynamic
proﬁle, pathological ﬁndings, and therapeutic approach/response.
Hemolytic anemia as an associated condition to the develop-
ment of pre-capillary PH has been changed into group 5 not just
because of the hemodynamic proﬁle. Indeed, recent cohorts on PH
associated to hemolytic anemias demonstrated a singular hemo-
dynamic proﬁle, as a consequence of high cardiac output, with
elevated pulmonary pressures and low pulmonary vascular resis-
tance (2–4). This fact was markedly relevant to support the deci-
sion of not including pulmonary vascular resistance as a mandatory
part of the deﬁnition of PH, since different cardiac output states
would demand different cutoffs of abnormality. Even more
importantly, the available data on the pathological ﬁndings and
treatment trials for patients with PH associated to hemolytic
anemia have also been reviewed. As mentioned by Klings et al. (2),
literature evaluating pulmonary arterial hypertension (PAH)
therapy in sickle cell disease associated PH is limited. In fact, there
is no consistent controlled data supporting the use of speciﬁc PAH
therapy in this setting. Regarding pathology ﬁndings, differently
from all other subforms of PAH included in group 1, many in-
consistencies also exist regarding the pulmonary vascular ﬁndings
in patients with sickle cell disease and PH. In the study from
Haque et al. (5), 1 of the largest available series, most of the
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2883included patients present cirrhosis as a clear confounding factor for
the interpretation of the data.
Based on these 3 different aspects, hemolytic anemia was
changed into group 5 in the current classiﬁcation, until new data
support otherwise (6). It is undeniable that PH is a signiﬁcant
complication of hemolytic anemia, with strong prognostic impli-
cation and, as such, should be better understood in order to support
the use of speciﬁc treatment strategies. Such a situation also occurs
in other clinical conditions that may develop pre-capillary PH.
Sarcoidosis is a clear example of a clinical condition in which a
signiﬁcant proportion of patients may develop PH. Nevertheless,
the lack of appropriate pathological studies and treatment trials
prevent its inclusion into group 1, even considering those pre-
senting true pre-capillary PH.
The current classiﬁcation system for PH has limitations. For
instance, prevalence of each one of the forms of PH is not covered
by the current classiﬁcation system and this may overemphasize the
importance of group 1 over the other groups, and should be
considered in future reviews of the current classiﬁcation.
Nevertheless, it is important to highlight that for any speciﬁc
subform of PH, targeted therapies should be appropriately tested
instead of extrapolating the results from studies enrolling poten-
tially similar conditions. Also in this sense, hemolytic anemias, as
other clinical conditions within group 5, represent an open and
important ﬁeld for PH research.
Finally, the change in clinical classiﬁcation was proposed by 12
of the 13 members of the Task Force on Clinical Classiﬁcation and
approved by more than 85% of the attendees during the plenary
session of the 5th World Symposium held in 2013, in Nice, France.*Rogerio Souza, MD, PhD
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Troponin Immunoassays
The “Cholesterol” of the
Third Millennium?We read with interest the paper by White et al. (1), who reported
that both baseline troponin I levels and change at 1 year measured
with a latest-generation immunoassay are reliable predictors of
coronary heart disease, death, and myocardial infarction after
adjustment for the most important cardiovascular risk factors,
including sex, age, body mass index, diabetes, smoking, hyperten-
sion, total and high-density lipoprotein cholesterol, triglycerides,
and fasting glucose.
Since their original publication in 2002 (2) and the update in
2004 (3), the Adult Treatment Panel (ATP) III Guidelines have
represented a cornerstone for the management of high blood
cholesterol and related disorders. Although enthusiastically
awaited, the next update of this document (i.e., the ATP IV) has
not been published so far. The evidence for a substantial revision
of available recommendations is weak, however, because no
major progress has been made in the management of dyslipi-
demia in the past decade. Nevertheless, the data published
by White et al. (1), which conﬁrm previous ﬁndings from
separate investigations (4), support the notion that chronic
troponin elevations truly mirror a pathophysiological process
that is distinct from the acute increase more typically observed
in patients with myocardial infarction. Recent advances in our
understanding of the pathogenesis of ischemic heart disease
conﬁrm that the turnover of cardiospeciﬁc troponins is sub-
stantially increased in patients with coronary artery disease, and
their plasma levels signiﬁcantly correlate with the burden of
coronary atherosclerosis (5). As such, it seems now unques-
tionable that the assessment of these cardiospeciﬁc biomarkers
would provide a net incremental beneﬁt for cardiovascular risk
assessment, not only in patients with established coronary artery
disease, but also in the general population (4). While “waiting
for Godot” (i.e., the ATP IV), it seems reasonable to suggest
that the expert panel of the National Cholesterol Education
Program should not ignore the valuable information that car-
diospeciﬁc troponins may provide for the screening and pre-
vention of cardiovascular risk, especially when these biomarkers
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